Format

Send to

Choose Destination
  • PMID: 25513081 was deleted because it is a duplicate of PMID: 25436296
Hepatogastroenterology. 2014 Jul-Aug;61(133):1279-82.

Effects of ramosetron oral disintegrating tablets on gastric emptying: crossover study using the 13C-acetic acid breath test.

Abstract

BACKGROUND/AIMS:

Ramosetron is a new selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that reportedly has more potent antiemetic effects than other 5-HT3 receptor antagonists. The aim of this study was to determine the effect of ramosetron pretreatment on gastric emptying using the 13C-acetic acid breath test.

METHODOLOGY:

Ten healthy male and female volunteers participated in this randomized, twoway crossover study. After they had fasted overnight, the subjects were randomly assigned to receive 0.1 mg ramosetron 1 hour before ingestion of a test meal (200 kcal per 200 mL, containing 100 mg 13C acetate) or to receive the test meal alone. Under both conditions, breath samples were collected for 150 min following ingestion of the meal. Statistical comparison of the parameters between the two test conditions was performed.

RESULTS:

No significant differences in the calculated parameters, including T 1/2, T lag, GEC or β and κ, were observed between the two test conditions.

CONCLUSIONS:

The present study revealed that 0.1 mg ramosetron had no significant effect on the rate of gastric emptying. Thus, our results suggest that ramosetron can be administered safely, without gastrointestinal adverse effects, even to terminal cancer patients with delayed or accelerated gastric emptying abnormality.

PMID:
25436296
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center